RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
BioCryst
Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that executives
from BioCryst are scheduled to present and provide a corporate
summary and update regarding the Company's clinical programs at the 8th
Annual JMP Securities Healthcare Conference in New York on Tuesday, July
9, 2013 at 3:30 p.m. Eastern Time.
Links to a live audio webcast and replay of the presentation may be
accessed on the BioCryst website events page at http://investor.shareholder.com/biocryst/events.cfm.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals designs, optimizes and develops novel small
molecule drugs that block key enzymes involved in infectious and
inflammatory diseases, with the goal of addressing unmet medical needs
of patients and physicians. BioCryst currently has two late-stage
development programs: peramivir,
a viral neuraminidase inhibitor for the treatment of influenza, and ulodesine,
a purine nucleoside phosphorylase (PNP) inhibitor for the treatment of
gout. In addition, BioCryst has several early-stage programs: BCX4161
and a next generation oral inhibitor of plasma kallikrein for hereditary
angioedema and BCX4430,
a broad spectrum antiviral for hemorrhagic fevers. For more information,
please visit the Company's website at www.BioCryst.com.
This press release contains forward-looking statements, including
statements regarding future results and achievements. These statements
involve known and unknown risks, uncertainties and other factors which
may cause our actual results, performance or achievements to be
materially different from any future results, performances or
achievements expressed or implied by the forward-looking statements.
Please refer to the documents BioCryst files periodically with the SEC
and located at http://investor.shareholder.com/biocryst/sec.cfm.
BCRXW
BioCryst Pharmaceuticals
Robert Bennett, +1-919-859-7910
Source: BioCryst Pharmaceuticals, Inc.
News Provided by Acquire Media